A trial of Sparsentan in IgA nephropathy (IgAN)

Trial Profile

A trial of Sparsentan in IgA nephropathy (IgAN)

Phase of Trial: Phase II

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs Sparsentan (Primary)
  • Indications IgA nephropathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2018 New trial record
    • 27 Feb 2018 According to a Retrophin media release, the company is planning to initiate this trial during the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top